BPC-157 and ARA-290 for Post-Surgical Nerve Damage: Evidence Summary
- ARA-290 treatment for 28 days in sarcoidosis patients with small fiber neuropathy improved neuropathic symptoms and increased corneal nerve fiber density.
- Phase II trial data on ARA-290 improving neuropathic symptoms and nerve fibers in sarcoidosis; relevant to nerve damage repair (no BPC-157).
- BPC-157 improved axonal regeneration, myelin thickness, and motor function in rat sciatic nerve transection models.
- Compares ARA-290 (nerve-specific) with BPC-157 (broad repair) for post-surgical nerve pain; supports potential stacking.
- A medical resource characterizes ARA-290 as a tissue-protective peptide for nerve pain.
Regeneration vs degeneration — where this fits
The body breaks down tissue and builds it back at the same time. When breakdown outruns repair after surgery, nerve damage can stay. Most drugs reduce pain signals without fixing the nerve itself. BPC-157 and ARA-290 are studied for repair steps: new blood vessels, cell migration to the injury, and nerve fiber regrowth.
What it is
BPC-157 is a peptide studied in rat nerve injury models. ARA-290 is a peptide studied in human small fiber neuropathy trials. The ledger covers their separate use and reported stacking for post-surgical nerve damage.
How it works
BPC-157 is linked to angiogenesis and cytoprotection at the injury site in rat models. ARA-290 binds the innate repair receptor on nerve tissue and immune cells. Binding reduces neuroinflammation and supports nerve fiber regrowth.
Why it would work (logic chain)
If surgery cuts or stretches a nerve, then axons and myelin break down. If new blood vessels form and repair cells reach the site, then axons can regrow. If inflammation stays high, then regrowth slows. BPC-157 is proposed to aid the vessel and repair-cell steps. ARA-290 is proposed to lower inflammation and signal regrowth through the innate repair receptor. If both pathways run, then repair might increase.
Why people take it
People report post-surgical nerve pain or numbness that does not resolve. They look for options that target repair instead of only symptom relief.
How many people take it
Unknown. The ledger shows 8 Reddit posts, 5 X posts, and 3 other anecdote sources. No population count exists.
Evidence inventory
Sources total 28. Studies catalogued 11. Reddit posts 8. X posts 5. Other anecdote sources 3. Human claims 3. Preclinical claims 8. Anecdotal claims 17. Human data come from ARA-290 sarcoidosis trials. BPC-157 data are rat sciatic nerve transection studies. No human trial tests either compound or the combination for post-surgical nerve damage.
What scientists say
Rat study s1 showed BPC-157 improved axonal regeneration, myelin thickness, and motor function after sciatic nerve transection. Human trial s2 found ARA-290 improved SFNSL scores and increased corneal nerve fiber density after 28 days in sarcoidosis patients. Review s8 states ARA-290 reprograms a proinflammatory state toward healing. Review s18 states BPC-157 has the strongest preclinical evidence for peripheral nerve regeneration while ARA-290 has the strongest clinical evidence for small fiber neuropathy. No study tests the combination for post-surgical nerve damage.
What people say on Reddit
Reddit post s11 states: “I got a neuropathic pain due to nerve damage after surgery.” The user reports stacking BPC-157, TB-500, and ARA-290. Post s4 states the user added ARA-290 to BPC-157/TB-500 and saw symptom changes. Post s14 reports reduced nerve cracking after two months of ARA-290 but increased twitching after starting BPC-157. Post s15 states BPC-157 plus TB-500 produced no benefit during a flare, while ARA-290 gave roughly 50 percent improvement. Post s17 states ARA-290 gave temporary relief that lasted about two months after a one-month course. These are single-person reports, not controlled data.
What people say on X
X post s24 states ARA-290 at 2-4 mg daily paired with BPC-157 plus TB-500 for nerve repair and that results build over 3-4 weeks. Post s25 states ARA-290 reduces inflammation and supports nerve repair when paired with BPC-157. Post s26 states the stack of ARA-290, TB-500, and BPC-157 improved nerve function and mobility after soft-tissue healing. Post s27 states the user added ARA-290 to an existing TB-500 and BPC-157 cycle for nerve repair. These are individual accounts of perceived change.
What we do not know
No human clinical trial tests BPC-157 or the BPC-157 plus ARA-290 combination for post-surgical nerve damage. Long-term effects and safety in this setting are unknown. Species differences mean rat nerve data may not translate to humans.
Safety and limits
The ledger contains no safety data specific to post-surgical nerve damage use in humans. Evidence mix is mostly preclinical and anecdotal. Hash-chained sources verify integrity, not clinical truth. This is a research catalogue only.
Key evidence
38 more ranked claims
Low-confidence / auto-generated 3
Ask this article · 8 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.